Development of Anti-human KLRB1 Antibodies for Cancer Immunotherapy
Checkpoint blockade therapies work by blocking inhibitory immune interactions, thereby “releasing the brakes” on the immune system. An inhibitory receptor called KLRB1 has been found to be overexpressed in activated immune cells by scRNA-seq. The potential to enhance immune function by blocking KLRB1 was demonstrated in a gene knockout model. To block its receptor-ligand interaction, we have engineered human antibodies specific to KLRB1 by yeast display and directed evolution.